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Primary Immunodeficiency
Renfen Chen
Abstract
Primary immunodeficiency (PID) is a large group of rare diseases present with 
chronic, serious, or life-threatening infections and other immune complications 
caused by defects or dysfunction of human immune system. Unlike secondary 
immunodeficiency acquired from an environmental factor or other medical 
conditions, PIDs are initiated by genetic defects. PIDs are divided into innate/
adaptive immunodeficiencies, phagocytic deficiencies, complement deficien-
cies, and immune dysregulation. Due to the heterogeneous nature of the clinical 
presentations, diagnosis of PIDs can be of significant challenge. Review of clini-
cal history and physical examination is important for raising initial suspicion of 
PIDs, whereas laboratory testing is essential to establish a diagnosis. Laboratory 
investigation includes the assessment of antibody and cellular response, as well as 
evaluation of the phagocytic and complement system. Flow cytometry and genetic 
assays are generally served as confirmation tools to validate a diagnosis. The recent 
exponential increase of genetic analysis has facilitated the identification of known 
and novel mutations. The advances in understanding of the immune system, 
development of novel cellular and molecular methodologies, and increased clini-
cal awareness have led to significant improvement of disease management and 
clinical outcome for these diseases.
Keywords: primary immunodeficiency, innate immunity, adaptive immunity, 
phenotype, gene defect, infection, autoimmune disorder, classification,  
clinical awareness, laboratory diagnosis, flow cytometry, genetic testing, treatment, 
prognosis
1. Introduction
Primary immunodeficiency (PID) is a large group of rare diseases attributed 
to inborn genetic errors that impair different components of adaptive and innate 
immune system, resulting in chronic, serious infections, or other complications. 
The diseases are often accompanied by a predisposition to autoimmune disorders, 
autoinflammation, atopy, and malignancy [1–4]. Unlike secondary immunodefi-
ciency acquired from other diseases or conditions such as malnutrition, immuno-
suppression, or HIV infections, PIDs are triggered by genetic defects. Based on the 
abnormality of one or more components of human immunity, PIDs can be divided 
into antibody deficiencies, combined T- and B-cell deficiencies, deficiencies in the 
phagocytic or complement system, and immune dysregulation [1]. Diagnosis of 
these disorders requires good clinical awareness and specialized laboratory testing. 
Flow cytometry and genetic testing are essential to identify the phenotypic and 
genetic defects of the diseases and to confirm the diagnosis. Accurate diagnosis 
and efficient management are important for reducing morbidity and mortality in 
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patients with PID [2]. The chapter provides an overview of the classification and 
manifestation as well as the diagnosis and management of these disorders.
2. Prevalence
Individual type of PIDs is considered to be rare in the population; however, recent 
studies have shown that PIDs may be more common than previously estimated 1% 
of the population when all varieties are combined [5]. The prevalence of PIDs varies 
depending on the type of immunodeficiencies and is difficult to be precisely calcu-
lated as the number of diagnosed cases is rapidly increasing. A 2018 global survey 
from the Jeffrey Modell Centers Network (JMCN) reported the case of PID patients 
followed in the JMCN increased by 35.4% to 102,097, while the case of patients identi-
fied with a specific gene defect increased 21.8% to 67,308 during the same period [5]. 
Up to 2018, 354 distinct disorders with 344 different gene defects were recognized 
[6]. Of note, most of the cases reported are from developed countries. It is estimated 
that 70–90% of individuals living with a PID are undiagnosed [7], particularly in 
the area with poor medical condition and lacking laboratory resources. With the 
extensive application of exome or whole genome sequencing, it was predicted that the 
associated PID genetic defects would reach 1000 under current trend in next decade 
[5]. Table 1 listed the reported number of 18 most common PID defects among 354 
inborn errors of immunity [5]. As shown, antibody deficiencies have much higher 
occurrence rate against other types of the disorders. Studies also showed that the 
selective IgA deficiency has the highest prevalence worldwide with a range from 1 in 
Table 1. 
Global prevalence of PIDs reported by Jeffrey Modell Centers Network [5].
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223 to 1 in 1000 depending on ethnic background [8], while severe combined immu-
nodeficiency (SCID), although fatal, is much rarer (1 in 100,000) [9, 10].
3. Classification
The classification of PIDs is generally based on the defects of the major 
components of human immunity, such as innate/adaptive immunodeficiencies, 
phagocytic deficiencies, complement deficiencies, and immune dysregulation. 
The classification has evolved over time with more phenotypic and genetic defects 
identified [4, 11].
Table 2. 
The 2017 IUIS phenotypic categorization of PIDs [6, 11].
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The International Union of Immunological Societies (IUIS) expert committee, 
currently named as Inborn Errors of Immunity Committee, has been responsible for 
issuing the classification of PIDs every other year from 1970. The complete catalog 
of classification has now been widely used as a reference by clinicians and research-
ers. From 2013, IUIS published more user-friendly phenotypic classification in 
two formats: one is a pdf file, namely clinically oriented phenotype categorization 
in the Journal of Clinical Immunology, and the other is a csv file containing a 
comprehensive list of various disorders that can be downloaded from http://www.
iuisonline.org [6, 11]. The phenotypic categorization published in the journal has 
been well designed for clinical use, while the online list contains the most updated 
information demonstrated in a digital friendly excel format that can be sorted by 
phenotypic and genetic features, which are very useful for designing sequencing 
panels, disease code lists, and diagnostic algorithms.
The major category and subcategory of PIDs from the revised 2017 IUIS pheno-
typic classification are summarized in Table 2.
4. Clinical presentations
Patients with PID present highly heterogeneous clinical symptoms with 
increased susceptibility to infections and other immune complications [12, 13]. 
Recurrent infection is the hallmark of the PIDs although a variety of other clini-
cal manifestations may appear before the infection [13, 14]. In fact, noninfectious 
manifestations, such as gastrointestinal disorders,  hematological diseases, autoim-
mune/autoinflammatory conditions, atopy or malignancy, can be the predominant 
clinical presentations in some patients with underlying immunodeficiency [3, 15]. 
Furthermore, patients with PID also demonstrate overlapping symptoms and share 
similarities with many “routine” diseases.
4.1 Infections
Majority of patients with PID suffer mild to severe or life-threatening infections. 
The unique clinical characteristics of infections in PIDs are recurring, chronic, 
and can appear in multiple anatomic sites. Recurrent infections in both the sinuses 
and the respiratory tract, such as sinusitis, bronchitis, otitis, and pneumonia, are 
the most frequent symptoms observed in patients with PID [16], while recurrent 
systemic infections (e.g., meningitis and bacteremia) are also not rare [17, 18]. 
Patients with SCID may suffer from unusual or opportunistic infections leading to 
unexpected complications or death [19].
4.2 Autoimmune and autoinflammatory disorders
Autoimmune and autoinflammatory disorders are more frequently seen in some 
categories of the PIDs than in other diseases [20]. The associated conditions in PID 
individuals may present in  a single tissue or organ, such as autoimmune hemo-
lytic anemia, thrombocytopenia, and autoimmune thyroiditis, or affect multiple 
organs, exemplified by an related vasculitis, or resemble rheumatic symptoms such 
as (e.g., dermatomyositis, rheumatoid arthritis, and systemic lupus erythemato-
sus) [3, 20, 21]. To note, family members that carry the same gene mutation may 
present different types of autoimmune/autoinflammatory symptoms, or without 
such disorders [22]. In comparison with other types of defects, the autoimmune 
presentations are relatively common in PIDs with antibody deficiencies (e.g., 
CVID, selective IgA deficiency), and absence of initial components (C1–C4) of the 
classical complement system [23, 24].
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4.3 Gastrointestinal and hematological disorders
Patients with PID, particularly infants and young children, may manifest 
chronic diarrhea, malnutrition, and malabsorption. Some individuals may undergo 
infections in gastrointestinal tract, such as chronic giardiasis and rotavirus [25], 
while others may experience a variety of autoimmune or autoinflammatory dis-
orders including inflammatory bowel disease, atrophic gastritis with pernicious 
anemia, or gluten-sensitive enteropathy [20].
Hematological disorders, such as autoimmune hemolytic anemia, and/or neutro-
penia and/or thrombocytopenia, are also frequently seen in patients with CVID or 
selective IgA deficiency [26]. Patients with the Wiskott-Aldrich syndrome, a disease 
characterized by variable defects in B- and T-lymphocyte function, can present with 
reduced platelet volume and significant thrombocytopenia [27].
4.4 Immunodeficiency syndromes
PID patients may also present with a syndrome complex. For example, recur-
rent bacterial/fungal infections and chronic inflammation of the gastrointestinal 
and respiratory tract often present in patients with chronic granulomatous disease, 
while an individual suffering from Wiskott-Aldrich syndrome may have manifesta-
tions of eczema, recurrent bacterial infections, autoimmune disorders, and throm-
bocytopenia [27]. In addition, congenital heart disease and hypocalcemic tetany 
frequently appear in a newborn baby with the DiGeorge syndrome [28, 29]. In fact, 
the investigation of patients with a syndrome derived from immunodeficiency may 
trigger an early diagnosis of PID before the typical immunodeficiency symptoms 
appear [4].
4.5 Malignancy
Compared to individuals with a healthy immune system, patients with PID 
are expected to have higher prevalence and/or broader spectrum of malignancies 
[30]. A study showed that lymphoma, the most common malignancy seen in PID 
patients, has increased 10-folds in male and 8.34-folds in female compared to 
age-matched controls [31]. Other types of cancer with higher frequency in PIDs are 
leukemia, digestive tract cancers, and virus-induced cancers [30]. Interestingly, 
the four most common cancers routinely occurred in men and women (lung, colon, 
breast, and prostate cancers) do not have significant elevation in subjects diagnosed 
with PID [31]. Evidence also demonstrated that patients with specific forms of 
immunodeficiency caused by highly penetrant gene defects have higher risk of 
developing cancer [32].
5. Clinical investigation
Early diagnosis of PID is critical for reducing morbidity or mortality and 
improving treatment outcomes. Review of clinical and family history and physi-
cal examination are the first steps in evaluating the need for further laboratory 
investigation.
The differentiation of PIDs from other medical conditions can be complicated 
as the symptoms of infection (e.g., sinusitis, bronchitis, pneumonia, gastroenteri-
tis, meningitis, or sepsis) and other manifestations often present in patients with 
non-PID. Hence, it is important to delineate the infectious organisms, the pattern of 
infections, and clinical pictures for guiding the clinical judgment, prior to focusing 
on laboratory testing.
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Due to the highly variable clinical presentations and low frequency of the PIDs, 
the diagnosis of patients is often delayed for years. To raise clinical awareness, 
JMCN has promoted 10 warning signs for children and adults (Table 3). Patients 
presenting with two or more of the clinical warning signs should be prompted for 
further investigation for the possible underlying immunodeficiencies and referred 
to immunologists for proper disease management.
6. Laboratory diagnosis
The laboratory testing is essential to diagnose and delineate the immunologic 
defects of PIDs. Patients with clinical suspicion should be further investigated for 
the response of innate immunity and adaptive immunity [33, 34]. Table 4 listed the 
most common tests used for initial screening of PIDs.
6.1 Evaluation of humoral immunity
Measurement of serum immunoglobulins is the first-line test for evaluating 
B-lymphocyte functions. Quantitative measurements of IgG, IgA, IgM, and IgE 
will identify either hypogammaglobulinemia or deficiency of an individual class of 
immunoglobulins. Evaluation of IgG subclasses may be required when a patient has 
strong implication of humoral immunodeficiency but the total IgG is normal. To 
be mindful, the results of immunoglobulin quantitation must be interpreted with 
appropriate age-specific ranges. Assessment of antibody responses to immunization 
with protein antigens (e.g., tetanus or diphtheria toxoids) and polysaccharide anti-
gens (e.g., pneumococcal capsular) is another way to evaluate humoral immunity, 
Table 3. 
Clinical warning signs of PIDs.
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although note is to be taken that live viral vaccines must be restricted to a patient 
with underlying immunodeficiency [35].
6.2 Evaluation of cellular immunity
Delayed-type hypersensitivity (DTH) skin test is commonly used to screen 
whether the patient has intact cell-mediated immune response. A positive DTH skin 
test generally rules out the possible defect of cellular immunity [36]. Nevertheless, the 
test requires that individuals must have sufficient prior exposure and sensitization to 
the testing antigen; therefore, it may not be suitable for infants and young children. 
Quantitation of T-lymphocytes (CD3, CD4, CD8) in peripheral blood is able to 
indirectly reflect the aberrant cellular immunity and can be easily performed by flow 
cytometry. More specialized T-cell function tests would provide in-depth informa-
tion in immune system, which include the assessment of lymphocyte proliferation in 
response to stimulus such as mitogens (e.g., phytohemagglutinin, ConA, and PMA), 
or specific antigens (e.g., candida). Furthermore, in vitro measurements of intra- and/
or extracellular cytokine responses (e.g., interleukin 2, interferon-gamma, BAFF, and 
TNF) are informative for the investigation of T- and B-lymphocyte regulation [37].
6.3 Evaluation of phagocytic function
Leukocyte count and differential can assess the phagocytic disorders such as con-
genital agranulocytosis or cyclic neutropenia. Phagocytic function can be indirectly 
Table 4. 
Initial laboratory tests for PIDs.
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assessed by traditional nitroblue tetrazolium (NBT) assay, which measures 
phagocytic cells’ killing capability in response to an oxidative burst. More recently, 
a simpler dihydrorhodamine 123 (DHR) assay based on flow cytometry has replaced 
NBT test for assisting the diagnosis of chronic granulomatous disease (CGD), Rac2 
deficiency, and complete myeloperoxidase deficiency [38, 39]. Other complicated 
in-vitro functional methods such as the measurement of directed cell movement 
(chemotaxis), ingestion (phagocytosis), and intracellular killing (bactericidal activ-
ity) are available in some specialized laboratories [40].
6.4 Evaluation of NK function
The importance of evaluating NK cells in human immunity has been previously 
underscored, and this is supported by two evidences: significantly increased number 
of patients with reduced NK cells and/or functions, and over 40 genetically defined 
congenital immunodeficiencies present with impaired NK cell functions [41]. There 
are several methods utilized for the examination of NK cell functions including 
51chromium  release assay, flow cytometry-based perforin/granzyme expression 
and CD107a degranulation. These assays are particularly valuable for the patients 
suspected of primary hemophagocytic lymphohistiocytosis [42, 43].
6.5 Evaluation of the complement system
The complement system can be evaluated by measuring the level or function 
of complement proteins that are involved in the classical and alternative activa-
tion pathways. C3 and C4 are the complements routinely tested. Quantitative and 
functional assay of C1 esterase inhibitor is essential for the diagnosis of hereditary 
angioedema. Assays of CH50 and AH50 are, respectively, used to measure the 
overall complement activity in the classical or alternative pathway. Combining 
the results of CH50 and AH50 is indicative for further investigation of individual 
complement proteins that initiate the classical or alternative pathway or common 
terminal pathway [44].
6.6 Flow cytometry
As our understanding of the defect or dysfunction of immune system 
increases, immunophenotypic and functional assays based on flow cytometry 
have been extensively used in identifying the abnormality of various cell 
types and their functions associated with certain diseases, including PIDs. 
Furthermore, flow cytometry is also a favorable technique for the measurement 
of intra- and extracellular cytokine production (e.g., IL12, IFN, TNF, and TH17), 
cell surface protein expression (e.g., Foxp3, CTLA-4, and BTK), and cellular 
signaling pathways (e.g., phosphor-STAT) [45]. The information gained from 
flow cytometry analysis can assist not only in the diagnosis, monitoring, and 
treatment of the diseases but also in understanding the influence of immune 
system associated with genetic defects that are newly identified. Table 5 lists the 
flow cytometry assays used for common PID disorders. Most of the tests listed 
are required to be undertaken in a specialized laboratory, with the exception of 
TBNK cell populations, memory B cells, and some function assays that can be 
performed in a routine diagnostic laboratory.
Proper instrument setting, standardized operating procedures, and good quality 
controls must be exercised when performing flow cytometric analysis, as flow 
cytometry is susceptible to assay variation,. The reported data must include both 
percentage and absolute number of specific cell population. Moreover, appropriate 
age-matched reference ranges should also be provided in the final report [47, 48]. 
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Ideally, each laboratory should establish their own normal ranges, but this is often 
not feasible; alternatively, published reference ranges may be used if a proper 
validation has been undertaken.
To date, flow cytometry has also been widely used for evaluating cell functions. 
Traditionally, lymphocyte functions were tested by radioactive methods, such 
as cytotoxicity of T and NK cells (chromium release) or proliferation of T cells 
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(tritiated thymidine uptake). These approaches are still recognized as gold stan-
dard by some clinicians. However, radioactive methods have the following intrinsic 
limitations: involvement of radioactivity, labor intensive, high expertise required, 
and poor result reproducibility. Additionally, seeking for a consistent healthy 
Table 5. 
Phenotypic and functional assessment for PIDs by flow cytometry [45, 46].
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fresh blood as assay normal control and obtaining a proper reference range can 
be challenging in routine laboratory practice. Therefore, they have been gradually 
replaced by other methodologies, such as bioluminescence-based assay or flow 
cytometry–based assay, which use specific dye for the detection of cell prolifera-
tion (e.g., CFSE, PKH-2, or PKH-26) or cell death (e.g., 7AAD and Annexing V) 
[49]. Many assays based on flow cytometry have been increasingly popular as 
they are easier to perform, have quicker turnaround time, are nonradioactive, are 
capable of using whole blood, and are more robust compared to the traditional 
radioactive assays.
Table 6. 
The advantages, limitations and recommendations of genetic technologies [50, 53].
Rare Diseases
12
6.7 Genetic testing
Genetic testing plays a critical role in patients with PID in confirming diagnosis, 
predicting the prognosis, assessing the influences of genotype-phenotype associa-
tions, and family planning [50, 51]. Besides, early and accurate molecular diagnosis 
is vital for guiding the selection of appropriate treatment including genetic therapy. 
Several molecular tests are available in identifying the genetic defects of PIDs, such as 
chromosomal analysis, fluorescence in situ hybridization, chromosomal microarray, 
single gene by Sanger sequencing, gene panels by massively parallel, whole exome, 
and genome by next-generation sequencing [52]. The selection of these assays should 
consider their inherent advantages and limitations [50, 53]. The summary of these 
tests is shown in Table 6. Recent emerged simple molecular assays for measuring 
circular DNA segments namely T-cell receptor excision circles and kappa-deleting 
recombination excision circles, based on quantitative PCR amplification of DNA 
extracted from dried blood spots, enable for a quick screening of newborn SCID [54].
The choice of specific gene(s) for examination is suggested by the patient’s clini-
cal history and phenotypical and functional results. Clinicians are required to have 
a basic understanding of the utility, accessibility of different genetic approaches. 
The selection criteria of molecular methodology should be based on the greatest 
odds of achieving the diagnosis within an acceptable time frame with the most 
cost-effective test. There is no specific algorithm for genetic testing in patients 
with PID as individual’s genetic mutation is often unique, the technology, cost, and 
the assay turnaround time are constantly changing, and each molecular method 
has inherent advantages and limitations. Practically, two or more approaches are 
often used together to achieve an optimal diagnosis [50]. For example, single gene 
Sanger sequencing is considered to be not only a simple and reliable assay for testing 
patients with known monogenic mutations of PID or their family members, but it 
can also serve as a tool for confirming the genetic variants detected by whole exome 
sequencing. When assessing large numbers of mutations, gene panels or whole 
genome/exome approach may be more cost-effective and faster than single gene 
analysis. Since genetic testing in primary immunodeficiency is highly personalized, 
and a specific genetic mutation does not always translate into a disease, test results 
must be interpreted with caution by genetic consultants and immunologists.
The recent advances of sequencing technologies have facilitated the genomic 
assays to become the standard of care in some hospitals although these techniques 
may face the challenges of cost, accessibility, and interpretation issues. The expo-
nential growth of genetic analysis by next-generation sequencing and other novel 
molecular technologies has enabled quick identification of known and novel muta-
tions, which contributed to a dramatic expansion of the number and types  
of PIDs [16, 53, 55].
7. Treatment
Treatments for PIDs involve preventing and controlling recurrent infections, 
treating symptoms, strengthening the immunity, and treating the underlying cause 
of the immune defects. Illness associated with PIDs such as autoimmune disorders 
or malignancies should also be managed [1, 13].
More aggressive and/or longer course of antibiotics than “normal infections” is 
usually prescribed in patients with PID, in order to control the infections caused by 
bacteria or fungi. Some patients may require prolonged antibiotic therapy to pre-
vent infections and permanent damage to organs [13]. Routine immunizations can 
also provide protective immunity to those at risk of infections, but the attenuated 
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vaccines such as oral polio and measles-mumps-rubella might not be suitable for 
children with PIDs. For viral infection, interferon-gamma therapy may be of choice 
besides other antiviral drugs routinely used (e.g., amantadine and acyclovir) [13]. 
In patients with chronic granulomatous disease, using granulocyte colony–stimulat-
ing factor, a glycoprotein that is able to stimulate the proliferation/differentiation 
and improve the functions of neutrophil, can help increase the levels of immune-
strengthening leukocytes to control the infections [56].
Immunoglobulin replacement has been the pillar of therapy for recurrent 
infections of PIDs, since around 60% of PID cases have impaired antibody 
production [57]. In fact, most of these patients will require life-time immuno-
globulin replacement therapy. Immunoglobulin can be delivered either intrave-
nously (abbreviated IVIG) or subcutaneously (abbreviated SCIG). The choice 
of which route depends on the circumstance although both of them have been 
demonstrated to be effective. Because higher IgG levels can be obtained through 
intravenous administration, IVIG has been routinely used for preventing serious/
recurrent infections [58]; however, SCIG has recently emerged as a popular route 
for delivery due to its fewer side effects and greater flexibility [57, 59]. Future 
research direction is focusing on more precise IgG replacement in PIDs, such as 
the development of IgG subclass-specific enriched preparation and microbe-
specific IgG [58].
Table 7. 
Current strategies for the treatment of PIDs [1, 13, 66].
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Apart from controlling infections, the considerable morbidity and mortality 
caused by noninfectious complications of PIDs can also be troublesome to clini-
cians. To standardize clinical practices and improve treatment outcome, British 
Society of Immunology has recently published the first set of recommendations for 
monitoring and managing the noninfectious complications of CVID [60].
Bone marrow transplantation (BMT) and hematopoietic stem cell transplanta-
tion (HSCT) are feasible options for a permanent cure for several types of life-
threatening immunodeficiency, with SCID in particular [61, 62]. Immune system 
can reconstitute when stem cells harvested from bone marrow or cord blood are 
transferred to the patients with PID. However, the successful rate of biological 
match, possibility of life-threatening graft-versus-host-disease, and the risk of 
uncontrolled infections following the destruction of the patient’s own immune 
system prior to the transplant should be well evaluated.
The technical advances of genetic engineering provide another hope to cure 
PIDs. Substantial progress has been made in the past decade in treating several 
types of PIDs (e.g., adenosine deaminase-SCID, SCID-X1, chronic granulomatous 
disorder, and Wiskott-Aldrich syndrome) with gene therapy [63–65]. Current treat-
ment scenario is mostly based on ex-vivo deliver of therapeutic transgene through 
viral vectors to autologous stem cells, followed by transplantation back to the same 
patient. Although the overall outcome from all the clinical trials targeting different 
PIDs has been extremely promising, however, serious adverse events (e.g., vector-
mediated oncogenesis) and high cost may be a hindrance to clinical trials and 
promotion of gene therapy [63, 65]. A summary of current strategies for treatment 
and management of PIDs is shown in Table 7.
8. Prognosis
The prognosis of patients with PID is extremely variable depending on the type 
of immune defects. Infants with SCID will die in the first 2 years of life without 
HSCT/BMT or gene therapy. Individuals who obtained stem cell transplantation in 
early childhood (before 3.5 months) have better prognosis [67]. Many PID patients 
who received proper medical care and treatments are able to live healthy and 
independent life for a long term. With the enhancement in managing infections and 
other complications and growing application of definitive therapies, the outcomes 
and long-term survival of PIDs have improved dramatically since the 1970s [13].
9. Conclusion
The investigation of PIDs has provided valuable insights to understand the 
specific gene defect that impairs the immune system. Flow cytometry and genetic 
testing enable to identify existing and novel phenotypes and genotypes as well as 
their impact on PIDs. The applications of flow cytometry and genetic technologies 
have expanded dramatically with more types of PID is defined, and the use of mass 
sequencing technologies has accelerated the identification of novel disorders. To 
efficiently use these complex assays, clinicians should have a good understanding 
of these methods and know how to interpret the results for diagnosis and disease 
management [33].
The management of patients with PID is based on three aspects of diagnosis: 
suspicious clinical manifestations, aberrant results of immune response, and the 
underlying genetic defect [4]. However, the diagnosis of PIDs may confront signifi-
cant challenges: there are large numbers of variable types of PIDs to be recognized 
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and most of them have alike clinical presentations with common diseases; immuno-
deficiencies derived from multiple gene defects can share similar symptoms, and a 
defect in the same gene may have various clinical manifestations [1]. While severe 
forms of PIDs are relatively easier to be recognized, milder immunodeficiencies 
may not raise alertness until typical presentation occurs [68, 69]. Additionally, the 
criteria for constituting a PID diagnosis are subjective, for example, the degree 
of frequency and the severity of the infections for establishing the diagnosis 
are unclear, the association of PIDs with autoimmune disorder or malignancy is 
ambiguous, and some individuals may not have noticeable symptoms apart from 
laboratory findings. Furthermore, advanced laboratory examination such as spe-
cialized flow cytometric and genetic analysis is not always easy to access. All these 
factors may contribute to delayed or missed diagnosis of the diseases.
To combat the challenges, clinical warning signs of PIDs should be disseminated 
to all clinicians for raising earlier recognition of the diseases, and an immunologist 
must be consulted for proper diagnosis and management. Due to the complexity 
of clinical presentations and large number of disease types, the use of scoring 
system based on the codes of the international classification of PIDs [69] assisted by 
artificial intelligence may be beneficial for clinicians to differentiate these disorders 
from other diseases and raise initial recognition. The recent advances in under-
standing the human immune system, development of novel cellular and molecular 
assays, and collaborations from the international/national organizations have led to 
significant increase of clinical awareness and cases diagnosed and improvement of 
disease management and treatment outcomes for PIDs.
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